Kangmei Pharmaceutical Co., Ltd. (SHA:600518)
China
· Delayed Price · Currency is CNY 1.870
-0.010 (-0.53%)
At close: Mar 9, 2026
Kangmei Pharmaceutical Revenue
Kangmei Pharmaceutical had revenue of 1.38B CNY in the quarter ending September 30, 2025, a decrease of -1.22%. This brings the company's revenue in the last twelve months to 5.28B, up 1.18% year-over-year. In the year 2024, Kangmei Pharmaceutical had annual revenue of 5.19B with 6.47% growth.
Revenue (ttm)
5.28B
Revenue Growth
+1.18%
P/S Ratio
4.90
Revenue / Employee
1.25M
Employees
4,233
Market Cap
25.86B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.19B | 315.12M | 6.47% |
| Dec 31, 2023 | 4.87B | 693.87M | 16.60% |
| Dec 31, 2022 | 4.18B | 27.63M | 0.67% |
| Dec 31, 2021 | 4.15B | -1.26B | -23.27% |
| Dec 31, 2020 | 5.41B | -6.03B | -52.72% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chengdu Kanghong Pharmaceutical Group | 4.67B |
| Hubei Jumpcan Pharmaceutical | 6.14B |
| Livzon Pharmaceutical Group | 11.85B |
| Shijiazhuang Yiling Pharmaceutical | 6.01B |
| Zhejiang Huahai Pharmaceutical | 8.71B |
| Tianjin Pharmaceutical Da Ren Tang Group Corporation | 5.37B |
| Dizal (Jiangsu) Pharmaceutical | 801.14M |
| Jiangsu Nhwa Pharmaceutical Co., LTD | 6.02B |